MSc MD - Apogee Therapeutics, Senior Development
| APGE Stock | 43.46 0.60 1.40% |
Executive
MSc MD is Senior Development of Apogee Therapeutics, Common
| Address | 221 Crescent Street, Waltham, MA, United States, 02453 |
| Phone | 650-394-5230 |
| Web | https://www.apogeetherapeutics.com |
Apogee Therapeutics, Management Efficiency
The company has return on total asset (ROA) of (0.1852) % which means that it has lost $0.1852 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2565) %, meaning that it created substantial loss on money invested by shareholders. Apogee Therapeutics,'s management efficiency ratios could be used to measure how well Apogee Therapeutics, manages its routine affairs as well as how well it operates its assets and liabilities. As of November 25, 2024, Return On Tangible Assets is expected to decline to -0.22. In addition to that, Return On Capital Employed is expected to decline to -0.26. As of November 25, 2024, Total Assets is expected to decline to about 304.4 M. In addition to that, Non Current Assets Total is expected to decline to about 1.6 MSimilar Executives
| Showing other executives | EXECUTIVE Age | ||
| Shelley Gretlein | FARO Technologies | N/A | |
| Chris Cole | Bridgford Foods | N/A | |
| Adam Deckinger | Tyson Foods | 48 | |
| Jerry Holbrook | Tyson Foods | N/A | |
| Timothy Last | Iridium Communications | N/A | |
| David JD | FARO Technologies | N/A | |
| Michael Fortin | Natural Alternatives Internatio | 47 | |
| Thomas JD | FARO Technologies | 62 | |
| Sean Cornett | Tyson Foods | N/A | |
| Allen Muhich | FARO Technologies | 57 | |
| Kathleen Morgan | Iridium Communications | 56 | |
| Jeffrey Sexton | FARO Technologies | 62 | |
| Jason Pollock | FARO Technologies | N/A | |
| Michael OConnor | Iridium Communications | N/A | |
| Michael Bridgford | Bridgford Foods | 42 | |
| Jacqueline Hanson | Tyson Foods | 55 | |
| Kenneth Levy | Iridium Communications | N/A | |
| Roger Isern | FARO Technologies | N/A | |
| Melanie Boulden | Tyson Foods | 51 | |
| Lori Bondar | Tyson Foods | 63 | |
| Phillip Delnick | FARO Technologies | N/A | |
Management Performance
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.19 |
Apogee Therapeutics, Leadership Team
Elected by the shareholders, the Apogee Therapeutics,'s board of directors comprises two types of representatives: Apogee Therapeutics, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Apogee. The board's role is to monitor Apogee Therapeutics,'s management team and ensure that shareholders' interests are well served. Apogee Therapeutics,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Apogee Therapeutics,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Carl MD, Chief Officer | ||
| Noel Kurdi, Vice Relations | ||
| Drew Badger, Senior Toxicology | ||
| Monica Forbes, Senior Finance | ||
| Matthew JD, General Counsel | ||
| Jane Henderson, Chief Officer | ||
| Dan Mulreany, Senior Strategy | ||
| Rebecca Dabora, Chief Officer | ||
| Mehrak Kiankarimi, Senior Operations | ||
| Wendy AspdenCurran, Senior Operations | ||
| Michael MD, CEO Director | ||
| Emily Cox, VP People | ||
| MSc MD, Senior Development |
Apogee Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Apogee Therapeutics, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.19 | ||||
| Current Valuation | 1.96 B | ||||
| Shares Outstanding | 43.42 M | ||||
| Shares Owned By Insiders | 11.71 % | ||||
| Shares Owned By Institutions | 88.29 % | ||||
| Number Of Shares Shorted | 6.81 M | ||||
| Price To Book | 3.37 X | ||||
| EBITDA | (83.98 M) | ||||
| Net Income | (83.98 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Apogee Therapeutics, is a strong investment it is important to analyze Apogee Therapeutics,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Apogee Therapeutics,'s future performance. For an informed investment choice regarding Apogee Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Apogee Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Apogee Therapeutics,. If investors know Apogee will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Apogee Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.43) | Return On Assets (0.19) | Return On Equity (0.26) |
The market value of Apogee Therapeutics, is measured differently than its book value, which is the value of Apogee that is recorded on the company's balance sheet. Investors also form their own opinion of Apogee Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Apogee Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Apogee Therapeutics,'s market value can be influenced by many factors that don't directly affect Apogee Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Apogee Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Apogee Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Apogee Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.